


# Lipid-Lowering Treatment Selector

Charts revised February 2019. Full information available at [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org)

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV/c	ATV/r	DRV/c	DRV/r	LPV/r	DOR	EFV	ETV	NVP	RPV	MVC	BIC/F/TAF	DTG	EVG/c/F/TAF	EVG/c/F/TDF	RAL	FTC or 3TC	F/TAF	TDF	ZDV
<b>Statins</b>																				
Atorvastatin	↑822%	↑	↑290%	↑	↑490%	↓2%	↓43%	↓37%	↓	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔	
Fluvastatin	↑	↑	↑	↑	↔	↔	↑	↑	↔	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔	
Lovastatin	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔	
Pitavastatin	↑	↑ <sup>a</sup>	↑	↓26%	↓20%	↔	↓11%	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔	
Pravastatin	↑	↑	↑	↑	↑81%	↔	↓44%	↓	↔	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔	
Rosuvastatin	↑242%	↑213%	↑93%	↑48%	↑107%	↔	↔	↔	↔	↔	↔	↔	↔	↑38%	↑38%	↔	↔	↔	↔	
Simvastatin	↑	↑	↑	↑	↑	↔	↓68%	↓	↓	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔	
<b>Fibrates</b>																				
Bezafibrate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
Clofibrate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
Fenofibrate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
Gemfibrozil	↔	↓	↔	↓	↓41%	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
<b>Other</b>																				
Evolocumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
Ezetimibe	↑	↑	↑	↓↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	

## Colour Legend



No clinically significant interaction expected.

These drugs should not be coadministered.

Potential interaction which may require a dose adjustment or close monitoring.

Potential interaction predicted to be of weak intensity.  
No *a priori* dosage adjustment is recommended.

## Text Legend

- ↑ Potential increased exposure of the lipid-lowering drug
- ↓ Potential decreased exposure of the lipid-lowering drug
- ↔ No significant effect

Numbers refer to increase or decrease in AUC as observed in drug-drug interaction studies.

## Notes

a Coadministration with unboosted atazanavir increased pitavastatin AUC by 31%.